Article
JAK2 mutation status, hemostatic risk factors and thrombophilic factors in essential thrombocythemia (ET) patients.
Folia histochemica et cytobiologica - 1 Jan 2011
Sokołowska Bożena, Nowaczyńska Aleksandra, Bykowska Ksenia, Chocholska Sylwia, Wejksza Katarzyna, Walter-Croneck Adam, Gromek Tomasz, Kowalska Anna M, Kandefer-Szerszeń Martyna, Dmoszyńska Anna
Abstract excerpt
The recently discovered JAK2 V617F point mutation, found in 50-60% of ET patients, has been reported to be associated with a higher risk of thrombotic events. In this study, we explored if JAK2 V617F mutation, or coexisting thrombophilic and hemostatic risk factors, contributed to these complications. We examined 32 patients with ET, and looked for pathogenetic JAK2 V617F mutation and prothrombotic genes...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.